Prelude Therapeutics (PRLD) Non-Current Assets (2019 - 2026)

Prelude Therapeutics has disclosed Non-Current Assets across 8 years of filings, most recently posting $35.0 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $35.0 million, down 9.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $145.1 million (down 9.79% YoY), and the FY2025 annual result was $35.6 million, down 10.09% from the prior year.
• Non-Current Assets came in at $35.0 million for Q1 2026 at Prelude Therapeutics, down from $35.6 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $42.1 million in Q4 2023 to a low of $10.4 million in Q2 2022.
• The 5-year median for Non-Current Assets is $35.6 million (2025), against an average of $30.0 million.
• Across the five-year window, Non-Current Assets surged 190.11% in 2022 and fell 10.8% in 2025, its largest moves.
• Prelude Therapeutics' Non-Current Assets stood at $16.1 million in 2022, then surged by 161.02% to $42.1 million in 2023, then dropped by 5.84% to $39.6 million in 2024, then decreased by 10.09% to $35.6 million in 2025, then declined by 1.61% to $35.0 million in 2026.
• The last three Non-Current Assets figures came in at $35.0 million (Q1 2026), $35.6 million (Q4 2025), and $36.4 million (Q3 2025), per Business Quant data.